Abbott receives FDA authorization for new Chagas assay The U.

Meals and Medication Administration today accepted the initial test for make use of as an additional, more specific test on individual serum or plasma specimens discovered to maintain positivity for antibodies to Trypanosoma cruzi . T. Cruzi causes Chagas disease, a significant and possibly fatal parasitic infection.The test, called the ABBOTT ESA Chagas [Trypanosoma cruzi Antigen], is an in vitro enzyme strip assay for the qualitative recognition of antibodies to T. Cruzi. There are currently two donor screening lab tests certified to detect antibodies to T. Cruzi; however, this would be the first test licensed as a supplemental test. Related StoriesDiabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of PolyphotonixImproved results yielded from new ChIP-seq protocolNew era of RNAscope products for RNA-biomarker analysis in FFPE cells released This test will help health care experts to supply counseling to donors with positive screening test results, said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research.In the aftermath of the recent scandals involving fake peer reviewers, many journals have decided to turn off the reviewer-suggestion option on their manuscript-submission systems. But that move is probably not enough, as the publisher Hindawi uncovered this past springtime. Although Hindawi doesn’t let authors suggest reviewers because of their manuscripts, it decided to examine the peer-review information for manuscripts submitted in 2013 and 2014 for possible fraud. The peer-review procedure found in Hindawi’s journals depends mainly on the expertise of its editorial board members and the guest editors of special issues, who are in charge of supervising the review of submitted manuscripts.5 Because the peer reviewers selected by the guest editors were not subject to any sort of independent verification, editors themselves could undermine the procedure in much the same way that authors or third-party agencies did elsewhere: by creating fake reviewer identities and addresses that they submitted reviews that are positive endorsing publication.